Shannon Parisotto Sells 3,714 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 3,714 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.66, for a total value of $1,038,657.24. Following the transaction, the executive vice president directly owned 4,807 shares in the company, valued at approximately $1,344,325.62. This represents a 43.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Down 0.6%

Shares of CRL opened at $279.70 on Friday. The business’s fifty day moving average price is $224.87 and its two-hundred day moving average price is $191.33. The firm has a market capitalization of $13.35 billion, a price-to-earnings ratio of -57.67, a PEG ratio of 2.92 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $288.02. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts predict that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of analyst reports. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Barclays reaffirmed an “overweight” rating and set a $300.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Royal Bank Of Canada increased their target price on Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Finally, JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $180.00 to $310.00 in a research report on Thursday, August 6th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $255.65.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $42,000. Sfam LLC acquired a new stake in Charles River Laboratories International during the 4th quarter worth approximately $43,000. Activest Wealth Management lifted its stake in Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $46,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.